New discovery could mean more targeted treatment for NI patients with prostate cancer
Queen's scientists say their research has thrown up some very promising results
Last updated 9th Oct 2019
Queen's University boffins have discovered a new way of predicting how aggressive prostate tumours are.
it is hoped their work could lead to better and more targeted personalised treatment for patients.
Indeed, In the long run, it may reduce or even replace the need for traditional invasive biopsies.
The new method uses images from computed tomography (CT) scans that are routinely collected from all patients.
The images are then analysed by a computer to extract hundreds of features, termed ‘radiomic features’, which have the potential to uncover disease characteristics that fail to be seen by the naked eye.
Prostate cancer is one of the most common forms of the disease, but the behaviour of an individual cancer is extremely variable.
Dr Suneil Jain, Principal Investigator from the Centre for Cancer Research & Cell Biology at Queen's University Belfast, said: “To predict the risk represented by a given tumour, ‘Gleason scores’ are typically assigned based on how a sample of the tumour appears under the microscope compared with normal prostate tissue.
"Patients are then classified as low, medium, or high risk depending on their Gleason score, level of prostate specific antigen (PSA) in the blood, and on size of the tumour and whether it has spread to other parts of the body.”
The research team used CT scans for 342 prostate-cancer patients acquired as a routine care prior to radiotherapy treatment.
Focusing on the prostate gland, the researchers then extracted and analysed over 500 radiomic features from each image. These features, along with the Gleason score and risk group classification for each patient, were used to ‘train’ a computer to be able to discriminate between patients in low- and high-risk groups, and between those with low and high Gleason score.
Dr Sarah Osman, Lead Investigator and Postdoctoral Research Fellow at Queen's University Belfast and the Belfast Health and Social Care Trust, explained: “This is the first CT-based radiomics investigation for this treatment site and it is showing very promising results. Although the present study will not revolutionize prostate cancer treatment by itself, it shows what could be possible in the future. We are building on collaborations with other institutes to provide datasets to validate our exciting findings and take this discovery forward.”
Professor Philippe Lambin from the Maastricht University and one of the co-inventors of Radiomics added: “Typically, there isn’t a huge amount of quantitative data in radiology reports. With the radiomics revolution, we need to look at medical images not just as pictures, but as quantitative data potentially useful for trials and routine care.”